Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
